In the last trading session, 1.5 million shares of the Ventyx Biosciences Inc (NASDAQ:VTYX) were traded, and its beta was 0.53. Most recently the company’s share price was $1.62, and it changed around -$0.05 or -2.99% from the last close, which brings the market valuation of the company to $114.55M. VTYX currently trades at a discount to its 52-week high of $11.48, offering almost -608.64% off that amount. The share price’s 52-week low was $1.65, which indicates that the current value has fallen by an impressive -1.85% since then. We note from Ventyx Biosciences Inc’s average daily trading volume that its 10-day average is 1.38 million shares, with the 3-month average coming to 1.87 million.
Ventyx Biosciences Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.67. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 3 recommended VTYX as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Ventyx Biosciences Inc is expected to report earnings per share of -0.55 for the current quarter.
Ventyx Biosciences Inc (NASDAQ:VTYX) trade information
Instantly VTYX has showed a red trend with a performance of -2.99% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.9000 on recent trading dayincreased the stock’s daily price by 14.74%. The company’s shares are currently down -26.03% year-to-date, but still down -11.96% over the last five days. On the other hand, Ventyx Biosciences Inc (NASDAQ:VTYX) is -22.12% down in the 30-day period. We can see from the shorts that 6.37 million shares have been sold at a short interest cover period of 3.4 day(s).
The consensus price target as assigned by Wall Street analysts is $45, which translates to bulls needing to increase their stock price by 96.4% from its current value. Analyst projections state that VTYX is forecast to be at a low of $6 and a high of $60.
Ventyx Biosciences Inc (VTYX) estimates and forecasts
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -148.81%. Ventyx Biosciences Inc earnings are expected to increase by 36.48% in 2025, but the outlook is positive 18.81% per year for the next five years.
Ventyx Biosciences Inc (NASDAQ:VTYX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 4.49% of Ventyx Biosciences Inc shares, and 85.04% of them are in the hands of institutional investors. The stock currently has a share float of 89.03%. Ventyx Biosciences Inc stock is held by 164.0 institutions, with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) being the largest institutional investor. By 2024-06-30, it held 9.4284% of the shares, which is about 5.83 million shares worth $13.47 million.
CITADEL ADVISORS LLC, with 9.3133% or 5.76 million shares worth $13.3 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Sep 30, 2024. The former held 1.78 shares worth $2.88 million, making up 2.51% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 1.71 shares worth around $2.77 million, which represents about 2.42% of the total shares outstanding.
